Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, today announced that the company will present updates on its ongoing Phase I clinical trials at the American Association for Cancer Research (AACR) Annual Meeting being held April 14–18, 2018, in Chicago. Poster presentations will feature updated data from Celyad’s THINK[1] trial, the new SHRINK[2] and LINK[3] trials in metastatic colorectal cancer, as well as data from a preclinical study showing that the addition of either the CD28 or 4-1BB co-stimulatory domains to CYAD-01 construct brings no benefit in terms of in vitro activity of the receptor.
Poster Presentation Details:
Poster Title: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia.
Poster Number: CT129
Session Title: Phase I Trials in Progress
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 12
Poster Title: The SHRINK clinical trial: A phase I study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.
Poster Number: CT123
Session Title: Phase I Trials in Progress
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 6
Poster Title: The LINK clinical trial: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer.
Poster Number: CT134
Session Title: Phase I Trials in Progress
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 17
Poster Title: NKG2D as a chimeric antigen receptor – DAP 10 provides optimal co-stimulation for NKG2D based CARs.
Session Title: Adoptive Cell Therapy 3
Poster Number: 3583
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 24, Poster Board 21
***END***
[1] THINK – THerapeutic Immunotherapy with CAR-T NKG2D
[2] SHRINK – Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D
[3] LINK – Locoregional Immunotherapy with NKG2D
Next News